These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25224412)

  • 61. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
    Sykes M; Abraham VS; Harty MW; Pearson DA
    J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
    Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease.
    Tijaro-Ovalle NM; Karantanos T; Wang HT; Boussiotis VA
    Front Immunol; 2019; 10():295. PubMed ID: 30891031
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Influence of donor Treg cells on GVHD and GVL effects after allogeneic bone marrow transplantation in mice].
    Cao J; Chen C; Zeng LY; Li ZY; Cheng H; Pan XY; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):181-4. PubMed ID: 20137143
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Role of NK cells in allogeneic hematopoietic stem cell transplantation--review].
    Li XH; Gao CJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):845-8. PubMed ID: 16928336
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation.
    Schmaltz C; Alpdogan O; Muriglan SJ; Kappel BJ; Rotolo JA; Ricchetti ET; Greenberg AS; Willis LM; Murphy GF; Crawford JM; van den Brink MR
    Blood; 2003 Mar; 101(6):2440-5. PubMed ID: 12424195
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
    Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
    J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.
    Chakraverty R; Eom HS; Sachs J; Buchli J; Cotter P; Hsu R; Zhao G; Sykes M
    Blood; 2006 Sep; 108(6):2106-13. PubMed ID: 16757687
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.
    Ohata J; Sakurai J; Saito K; Tani K; Asano S; Azuma M
    Clin Exp Immunol; 2002 Jul; 129(1):61-8. PubMed ID: 12100023
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?
    Sprangers B; Fevery S; Van Wijmeersch B; De Somer L; Waer M; Billiau AD
    Front Biosci; 2007 May; 12():4568-94. PubMed ID: 17485398
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
    Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recipient myeloid-derived immunomodulatory cells induce PD-1 ligand-dependent donor CD4+Foxp3+ regulatory T cell proliferation and donor-recipient immune tolerance after murine nonmyeloablative bone marrow transplantation.
    van der Merwe M; Abdelsamed HA; Seth A; Ong T; Vogel P; Pillai AB
    J Immunol; 2013 Dec; 191(11):5764-76. PubMed ID: 24190658
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Expansion of natural killer cell receptor (CD94/NKG2A)-expressing cytolytic CD8 T cells and CD4+CD25+ regulatory T cells from the same cord blood unit.
    Tanaka J; Sugita J; Kato N; Toubai T; Ibata M; Shono Y; Ota S; Kondo T; Kobayashi T; Kobayashi M; Asaka M; Imamura M
    Exp Hematol; 2007 Oct; 35(10):1562-6. PubMed ID: 17681668
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
    Sinkovics JG
    Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
    Xun CQ; Thompson JS; Jennings CD; Brown SA
    Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT.
    Rezvani K; Mielke S; Ahmadzadeh M; Kilical Y; Savani BN; Zeilah J; Keyvanfar K; Montero A; Hensel N; Kurlander R; Barrett AJ
    Blood; 2006 Aug; 108(4):1291-7. PubMed ID: 16627754
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants.
    Randolph SS; Gooley TA; Warren EH; Appelbaum FR; Riddell SR
    Blood; 2004 Jan; 103(1):347-52. PubMed ID: 12969970
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
    Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
    Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
    Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S
    Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
    Sheng L; Mu Q; Wu X; Yang S; Zhu H; Wang J; Lai Y; Wu H; Sun Y; Hu Y; Fu H; Wang Y; Xu K; Sun Y; Zhang Y; Zhang P; Zhou M; Lai B; Xu Z; Gao M; Zhang Y; Ouyang G
    Front Immunol; 2020; 11():1534. PubMed ID: 32849519
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.